
Epoetin5000 IU
Incepta Pharmaceuticals Ltd.
Erythropoietin is an erythropoiesis-stimulating agent (ESA), a recombinant form of human erythropoietin that stimulates red blood cell production.
Erythropoietin is an erythropoiesis-stimulating agent (ESA), a recombinant form of human erythropoietin that stimulates red blood cell production. It is FDA-approved and guideline-supported for the following established indications:
Important limitations: Erythropoietin is not indicated and is not FDA-approved for improvement of quality of life, fatigue, or general well-being; for cancer patients receiving hormonal agents, biologic products, or radiotherapy only (without concomitant myelosuppressive chemotherapy); for patients who are able to donate autologous blood; or for use in patients undergoing cardiac or vascular surgery. Therapy should target the lowest dose sufficient to reduce the need for RBC transfusion, not to normalize hemoglobin (see Precautions and Warnings for the boxed warning).
Dosing of Erythropoietin must be individualized by a physician based on the indication, baseline hemoglobin, rate and degree of hemoglobin rise, and clinical response. The goal is to use the lowest dose sufficient to reduce the need for RBC transfusion, not to normalize hemoglobin. Erythropoietin is given by intravenous or subcutaneous injection; it should never be self-adjusted by the patient without physician guidance.
| Indication | Typical Starting Dose | Notes |
|---|---|---|
| Anemia of CKD (dialysis, adult) | 50-100 Units/kg IV or SC, 3 times weekly | Initiate when hemoglobin <10 g/dL; reduce dose if hemoglobin approaches or exceeds 11 g/dL |
| Anemia of CKD (non-dialysis, adult) | 50-100 Units/kg IV or SC, 3 times weekly | Consider therapy only if hemoglobin <10 g/dL; individualize to minimize transfusion need |
| Anemia of CKD (pediatric, ≥1 month) | 50 Units/kg, 3 times weekly | Initiate when hemoglobin <10 g/dL; reduce dose if hemoglobin approaches or exceeds 12 g/dL |
| Zidovudine-associated anemia in HIV (adult) | 100 Units/kg IV or SC, 3 times weekly | May increase by 50-100 Units/kg at 4-8 week intervals (up to 300 Units/kg) if response inadequate |
| Chemotherapy-induced anemia (adult) | 150 Units/kg SC 3 times weekly, or 40,000 Units SC once weekly | Continue for at least 2 additional months of planned chemotherapy; discontinue after chemotherapy course ends |
| Chemotherapy-induced anemia (pediatric ≥5 years) | 600 Units/kg IV once weekly | Reduce or withhold as per hemoglobin response |
| Perioperative (elective, non-cardiac, non-vascular surgery) | 300 Units/kg/day SC for 15 days (10 days before, day of, and 4 days after surgery), or 600 Units/kg SC on days 21, 14, and 7 before surgery plus day of surgery | For patients with hemoglobin 10-13 g/dL at high risk of perioperative blood loss; venous thromboembolism prophylaxis is recommended |
Hemoglobin should be monitored regularly (e.g., weekly to every 2-4 weeks) during therapy, and doses adjusted by the treating physician; the drug should be withheld if hemoglobin rises too rapidly or exceeds target levels. Iron status should be evaluated and corrected before and during treatment. Do not shake the solution, as vigorous shaking may denature the product.
Common and serious adverse effects reported with Erythropoietin include:
Erythropoietin is contraindicated in patients with:
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.